Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Clin Cancer Res May 1 2012 18 (9) 2415-2415;

CCR Translations

  • CCR Translations
    For Breast Cancer Prognosis, Immunoglobulin Kappa Chain Surfaces to the Top
    Theresa L. Whiteside and Soldano Ferrone
    Clin Cancer Res May 1 2012 18 (9) 2417-2419; DOI:10.1158/1078-0432.CCR-12-0566

  • CCR Translations
    Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?
    Federica Catalanotti and David B. Solit
    Clin Cancer Res May 1 2012 18 (9) 2420-2422; DOI:10.1158/1078-0432.CCR-12-0626

CCR New Strategies

  • CCR New Strategies
    New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome
    Kristina A. Cole and John M. Maris
    Clin Cancer Res May 1 2012 18 (9) 2423-2428; DOI:10.1158/1078-0432.CCR-11-1409

Molecular Pathways

  • Molecular Pathways
    Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling
    Nadia B. Hassounah, Thomas A. Bunch and Kimberly M. McDermott
    Clin Cancer Res May 1 2012 18 (9) 2429-2435; DOI:10.1158/1078-0432.CCR-11-0755

  • Molecular Pathways
    Molecular Pathways: Old Drugs Define New Pathways: Non-Histone Acetylation at the Crossroads of the DNA Damage Response and Autophagy
    Oronza Antonietta Botrugno, Thomas Robert, Fabio Vanoli, Marco Foiani and Saverio Minucci
    Clin Cancer Res May 1 2012 18 (9) 2436-2442; DOI:10.1158/1078-0432.CCR-11-0767

Review

  • Review
    Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
    Pablo Perez-Moreno, Elisabeth Brambilla, Roman Thomas and Jean-Charles Soria
    Clin Cancer Res May 1 2012 18 (9) 2443-2451; DOI:10.1158/1078-0432.CCR-11-2370

Human Cancer Biology

  • Human Cancer Biology
    Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma
    Derek P. Simon, Thomas J. Giordano and Gary D. Hammer
    Clin Cancer Res May 1 2012 18 (9) 2452-2464; DOI:10.1158/1078-0432.CCR-11-2371

  • Human Cancer Biology
    Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype
    Richard C. Wu, Shujuan Liu, Jessica A. Chacon, Sheng Wu, Yufeng Li, Pariya Sukhumalchandra, James L. Murray, Jeffrey J. Molldrem, Patrick Hwu, Hanspeter Pircher, Gregory Lizée and Laszlo G. Radvanyi
    Clin Cancer Res May 1 2012 18 (9) 2465-2477; DOI:10.1158/1078-0432.CCR-11-2034

  • Human Cancer Biology
    Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
    Elliot L. Servais, Christos Colovos, Luis Rodriguez, Adam J. Bograd, Jun-ichi Nitadori, Camelia Sima, Valerie W. Rusch, Michel Sadelain and Prasad S. Adusumilli
    Clin Cancer Res May 1 2012 18 (9) 2478-2489; DOI:10.1158/1078-0432.CCR-11-2614

  • Human Cancer Biology
    IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
    Daniel Gorovets, Kasthuri Kannan, Ronglai Shen, Edward R. Kastenhuber, Nasrin Islamdoust, Carl Campos, Elena Pentsova, Adriana Heguy, Suresh C. Jhanwar, Ingo K. Mellinghoff, Timothy A. Chan and Jason T. Huse
    Clin Cancer Res May 1 2012 18 (9) 2490-2501; DOI:10.1158/1078-0432.CCR-11-2977

Cancer Therapy: Preclinical

  • Cancer Therapy: Preclinical
    The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
    Kim H.T. Paraiso, H. Eirik Haarberg, Elizabeth Wood, Vito W. Rebecca, Y. Ann Chen, Yun Xiang, Antoni Ribas, Roger S. Lo, Jeffrey S. Weber, Vernon K. Sondak, Jobin K. John, Amod A. Sarnaik, John M. Koomen and Keiran S.M. Smalley
    Clin Cancer Res May 1 2012 18 (9) 2502-2514; DOI:10.1158/1078-0432.CCR-11-2612

  • Cancer Therapy: Preclinical | Free Article
    Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
    Giorgia Migliardi, Francesco Sassi, Davide Torti, Francesco Galimi, Eugenia R. Zanella, Michela Buscarino, Dario Ribero, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Mauro Risio, Lorenzo Capussotti, Silvia Marsoni, Federica Di Nicolantonio, Alberto Bardelli, Paolo M. Comoglio, Livio Trusolino and Andrea Bertotti
    Clin Cancer Res May 1 2012 18 (9) 2515-2525; DOI:10.1158/1078-0432.CCR-11-2683

  • Cancer Therapy: Preclinical
    Spleen Cells from Young but Not Old Immunized Mice Eradicate Large Established Cancers
    Karin Schreiber, Ainhoa Arina, Boris Engels, Michael T. Spiotto, John Sidney, Alessandro Sette, Theodore G. Karrison, Ralph R. Weichselbaum, Donald A. Rowley and Hans Schreiber
    Clin Cancer Res May 1 2012 18 (9) 2526-2533; DOI:10.1158/1078-0432.CCR-12-0127

  • Cancer Therapy: Preclinical
    Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
    Adam M. Petrich, Violetta Leshchenko, Pei-Yu Kuo, Bing Xia, Venu K. Thirukonda, Netha Ulahannan, Shanisha Gordon, Melissa J. Fazzari, B. Hilda Ye, Joseph A. Sparano and Samir Parekh
    Clin Cancer Res May 1 2012 18 (9) 2534-2544; DOI:10.1158/1078-0432.CCR-11-1407

  • Cancer Therapy: Preclinical
    Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors
    Markus P. Ghadimi, Eric D. Young, Roman Belousov, Yiqun Zhang, Gonzalo Lopez, Kristelle Lusby, Christine Kivlin, Elizabeth G. Demicco, Chad J. Creighton, Alexander J. Lazar, Raphael E. Pollock and Dina Lev
    Clin Cancer Res May 1 2012 18 (9) 2545-2557; DOI:10.1158/1078-0432.CCR-11-2592

  • Cancer Therapy: Preclinical
    mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
    Alfredo A. Molinolo, Christina Marsh, Mohamed El Dinali, Nitin Gangane, Kaitlin Jennison, Stephen Hewitt, Vyomesh Patel, Tanguy Y. Seiwert and J. Silvio Gutkind
    Clin Cancer Res May 1 2012 18 (9) 2558-2568; DOI:10.1158/1078-0432.CCR-11-2824

  • Cancer Therapy: Preclinical
    Peptides Mimicking the Unique ARTS-XIAP Binding Site Promote Apoptotic Cell Death in Cultured Cancer Cells
    Natalia Edison, Tali-Haviv Reingewertz, Yossi Gottfried, Tali Lev, Dotan Zuri, Inbal Maniv, Marie-Jeanne Carp, Gil Shalev, Assaf Friedler and Sarit Larisch
    Clin Cancer Res May 1 2012 18 (9) 2569-2578; DOI:10.1158/1078-0432.CCR-11-1430

  • Cancer Therapy: Preclinical
    Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts
    Sunil J. Advani, Lisa Buckel, Nanhai G. Chen, Daniel J. Scanderbeg, Ulrike Geissinger, Qian Zhang, Yong A. Yu, Richard J. Aguilar, Arno J. Mundt and Aladar A. Szalay
    Clin Cancer Res May 1 2012 18 (9) 2579-2590; DOI:10.1158/1078-0432.CCR-11-2394

  • Cancer Therapy: Preclinical
    Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts
    Mark D. Walsh, Suzan K. Hanna, Jeremy Sen, Sumit Rawal, Carolina B. Cabral, Alex V. Yurkovetskiy, Robert J. Fram, Timothy B. Lowinger and William C. Zamboni
    Clin Cancer Res May 1 2012 18 (9) 2591-2602; DOI:10.1158/1078-0432.CCR-11-1554

  • Cancer Therapy: Preclinical
    Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy
    Celina García-García, Yasir H. Ibrahim, Violeta Serra, Maria Teresa Calvo, Marta Guzmán, Judit Grueso, Claudia Aura, José Pérez, Katti Jessen, Yi Liu, Christian Rommel, Josep Tabernero, José Baselga and Maurizio Scaltriti
    Clin Cancer Res May 1 2012 18 (9) 2603-2612; DOI:10.1158/1078-0432.CCR-11-2750

Imaging, Diagnosis, Prognosis

  • Imaging, Diagnosis, Prognosis
    Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer
    Remond J.A. Fijneman, Meike de Wit, Maral Pourghiasian, Sander R. Piersma, Thang V. Pham, Marc O. Warmoes, Mehrdad Lavaei, Chloe Piso, Fiona Smit, Pien M. Delis-van Diemen, Sietze T. van Turenhout, Jochim S. Terhaar sive Droste, Chris J.J. Mulder, Marinus A. Blankenstein, Els C. Robanus-Maandag, Ron Smits, Riccardo Fodde, Victor W.M. van Hinsbergh, Gerrit A. Meijer and Connie R. Jimenez
    Clin Cancer Res May 1 2012 18 (9) 2613-2624; DOI:10.1158/1078-0432.CCR-11-1937

Cancer Therapy: Clinical

  • Cancer Therapy: Clinical
    Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
    Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph Ludwig, Helen X. Chen, Laurence A. Doyle and Razelle Kurzrock
    Clin Cancer Res May 1 2012 18 (9) 2625-2631; DOI:10.1158/1078-0432.CCR-12-0061

  • Cancer Therapy: Clinical
    Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity
    Florian Heitz, Andreas du Bois, Justine Rochon, Stefanie Scheil-Bertram, Rita Hils, Annette Fisseler-Eckhoff, Jana Barinoff, Christine Kaub and Philipp Harter
    Clin Cancer Res May 1 2012 18 (9) 2632-2637; DOI:10.1158/1078-0432.CCR-12-0021

  • Cancer Therapy: Clinical
    The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
    Jason J. Luke, David R. D'Adamo, Mark A. Dickson, Mary Louise Keohan, Richard D. Carvajal, Robert G. Maki, Elisa de Stanchina, Elgilda Musi, Samuel Singer and Gary K. Schwartz
    Clin Cancer Res May 1 2012 18 (9) 2638-2647; DOI:10.1158/1078-0432.CCR-11-3203

  • Cancer Therapy: Clinical
    Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors
    Sameer Doshi, Liviawati Sutjandra, Jenny Zheng, Winnie Sohn, Mark Peterson, Graham Jang, Andrew T. Chow and Juan Jose Pérez-Ruixo
    Clin Cancer Res May 1 2012 18 (9) 2648-2657; DOI:10.1158/1078-0432.CCR-11-2944

  • Cancer Therapy: Clinical
    A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
    Klaus Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Martin Büchert, Ulrike Fasol, Clemens Unger, Jörn Krätzschmar, Roland Heinig, Oliver Boix and Olaf Christensen
    Clin Cancer Res May 1 2012 18 (9) 2658-2667; DOI:10.1158/1078-0432.CCR-11-1900

  • Cancer Therapy: Clinical
    Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer
    Setsuko K. Chambers, H-H. Sherry Chow, Mike F. Janicek, Janiel M. Cragun, Kenneth D. Hatch, Haiyan Cui, Cynthia Laughren, Mary C. Clouser, Janice L. Cohen, Heather M. Wright, Nisreen Abu Shahin and David S. Alberts
    Clin Cancer Res May 1 2012 18 (9) 2668-2678; DOI:10.1158/1078-0432.CCR-12-0261

  • Cancer Therapy: Clinical
    Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
    Steven G. DuBois, Louis Chesler, Susan Groshen, Randall Hawkins, Fariba Goodarzian, Hiroyuki Shimada, Greg Yanik, Michael Tagen, Clinton Stewart, Yael P. Mosse, John M. Maris, Denice Tsao-Wei, Araz Marachelian, Judith G. Villablanca and Katherine K. Matthay
    Clin Cancer Res May 1 2012 18 (9) 2679-2686; DOI:10.1158/1078-0432.CCR-11-3201

  • Cancer Therapy: Clinical
    A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
    Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, Matthew Tall, Adam Stewart, Florence Raynaud, Michelle Dawn Garrett, Martin Toal, Leon Hooftman, Johann Sebastian De Bono, Jaap Verweij and Ferry ALM Eskens
    Clin Cancer Res May 1 2012 18 (9) 2687-2694; DOI:10.1158/1078-0432.CCR-11-3165

Predictive Biomarkers and Personalized Medicine

  • Predictive Biomarkers and Personalized Medicine
    A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
    Marcus Schmidt, Birte Hellwig, Seddik Hammad, Amnah Othman, Miriam Lohr, Zonglin Chen, Daniel Boehm, Susanne Gebhard, Ilka Petry, Antje Lebrecht, Cristina Cadenas, Rosemarie Marchan, Joanna D. Stewart, Christine Solbach, Lars Holmberg, Karolina Edlund, Hanna Göransson Kultima, Achim Rody, Anders Berglund, Mats Lambe, Anders Isaksson, Johan Botling, Thomas Karn, Volkmar Müller, Aslihan Gerhold-Ay, Christina Cotarelo, Martin Sebastian, Ralf Kronenwett, Hans Bojar, Hans-Anton Lehr, Ugur Sahin, Heinz Koelbl, Mathias Gehrmann, Patrick Micke, Jörg Rahnenführer and Jan G. Hengstler
    Clin Cancer Res May 1 2012 18 (9) 2695-2703; DOI:10.1158/1078-0432.CCR-11-2210

  • Predictive Biomarkers and Personalized Medicine
    Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
    John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell, Todd M. Pitts, Anna Spreafico, Marileila Varella-Garcia, Lynne Bemis, Aik Choon Tan, Jaclyn M. Reinemann, Basel M. Touban, Arvind Dasari, S. Gail Eckhardt and Wells A. Messersmith
    Clin Cancer Res May 1 2012 18 (9) 2704-2714; DOI:10.1158/1078-0432.CCR-11-3167

Letters to the Editor

  • Letters to the Editor
    Population Pharmacokinetics of Busulfan in Children–Letter
    Laurent Nguyen, Angelo Paci and Gilles Vassal
    Clin Cancer Res May 1 2012 18 (9) 2715-2716; DOI:10.1158/1078-0432.CCR-11-3297

  • Letters to the Editor
    Population Pharmacokinetics of Busulfan in Children–Response
    Mirjam N. Trame, Martin Bergstrand, Mats O. Karlsson and Georg Hempel
    Clin Cancer Res May 1 2012 18 (9) 2717-2718; DOI:10.1158/1078-0432.CCR-12-0425

Corrections

  • Corrections
    Correction: Pancreatic Tumor Suppression by Benzyl Isothiocyanate Is Associated with Inhibition of PI3K/AKT/FOXO Pathway
    Clin Cancer Res May 1 2012 18 (9) 2719-2719; DOI:10.1158/1078-0432.CCR-12-0772

  • Corrections
    Correction: PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
    Clin Cancer Res May 1 2012 18 (9) 2720-2720; DOI:10.1158/1078-0432.CCR-12-0960

Back to top
PreviousNext
Clinical Cancer Research: 18 (9)
May 2012
Volume 18, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma
  • Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
  • The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
  • Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer
  • A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Jump to

  • Highlights
  • CCR Translations
  • CCR New Strategies
  • Molecular Pathways
  • Review
  • Human Cancer Biology
  • Cancer Therapy: Preclinical
  • Imaging, Diagnosis, Prognosis
  • Cancer Therapy: Clinical
  • Predictive Biomarkers and Personalized Medicine
  • Letters to the Editor
  • Corrections
Advertisement
  • Most Cited
  • Most Read
Loading
  • Immune Checkpoint Blockade Requires Macrophage CXCL9/CXCL10
  • PDAC and GATA6 Expression
  • Characterization of Glioblastoma Patient-Derived Xenografts
  • Guadecitabine and Carboplatin in Ovarian Cancer
  • Toxicity Management Affects Checkpoint Inhibitor Efficacy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement